PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

ASCO23: ‘Safety & efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid & CNS tumors’

Sylvester Comprehensive Cancer Center’s Dr. Macarena de la Fuente presents results from a Phase 1/2a study showing the experimental, targeted therapy may be effective in treating BRAF-altered solid tumors

ASCO23: ‘Safety & efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid & CNS tumors’
2023-05-25
(Press-News.org) MIAMI, FLORIDA (EMBARGOED UNTIL MAY 25, 2023, AT 5 P.M. ET) – An early-phase study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine along with other Cancer Centers, suggests that an experimental therapy may have promising results in treating cancers with BRAF gene alterations – including certain mutations not previously targeted by BRAF inhibitors.

The Phase 1/2a study looking at safety and dosing enrolled 113 patients and targeted a wide range of cancers, including high-grade glioma, low-grade glioma, colorectal cancer, papillary thyroid cancer, melanoma, pancreatic cancer, ovarian cancer, non-small cell lung cancer, anaplastic thyroid cancer, and others.

The BRAF protein is part of a communication pathway that controls vital processes in cells. Several alterations of the BRAF gene can cause mutant forms of the BRAF protein to be made, leading to cancer development. V600 mutations – including V600E, V600K, and V600R – are common in melanoma and certain other cancers. Currently available BRAF inhibitors target V600 mutations but do not target the much less common non-V600 mutations.

“Our study, which included adults and children with advanced, solid tumors that could not be surgically removed, showed promising activity against V600 and non-V600 BRAF mutant tumors, including primary central nervous system (CNS) tumors,” said Dr. Macarena de la Fuente, chief of Neuro-Oncology at Sylvester, whose research focuses on developing treatments for primary brain tumors. “The drug is well tolerated, comparing very favorably with other BRAF inhibitor therapies, with mostly low-grade adverse events at all dosing levels.”

In addition to its ability to target non-V600 mutations, the investigational drug, FORE8394, appears to thwart cancer cells’ ability to escape BRAF inhibition by activating another pathway, the MAPK signaling pathway.

“Combining a BRAF inhibitor and an MEK inhibitor is the most common approach to treating cancers with BRAF mutations. However, due to its pharmacological features, treatment with this drug does not result in paradoxical activation of the MAPK pathway avoiding the need for combination with an MEK inhibitor,” said de la Fuente, first author of the presentation involving a multicenter research team. She said the results support continuation of ongoing studies with the drug in tumors with BRAF “fusion” – a rare mechanism of BRAF activation – and in recurrent primary CNS tumors with BRAF V600E mutations.

The study was sponsored by Fore Biotherapeutics Inc. It was conducted by researchers at: Sylvester Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center, NY; HonorHealth Research Institute, Scottsdale, AZ; MD Anderson Cancer Center, Houston, TX; University of California, San Francisco; Baylor College of Medicine Texas Children's Cancer Center, Houston, TX; Community Health Network, Cancer Center, Anderson, IN; Pharma Polaris International Consulting Inc, San Marino, CA; Projections Research Inc, Phoenixville, PA; Audentes Consulting LLC, Fairfax, CA; Fore Biotherapeutics Inc., Philadelphia, PA.

# # #

(EMBARGOED UNTIL MAY 25, 2023, AT 5 P.M. ET)

END


[Attachments] See images for this press release:
ASCO23: ‘Safety & efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid & CNS tumors’ ASCO23: ‘Safety & efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid & CNS tumors’ 2

ELSE PRESS RELEASES FROM THIS DATE:

MD Anderson Research Highlights: ASCO 2023 Special Edition

2023-05-25
CHICAGO ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features presentations by MD Anderson researchers at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. In addition to these studies, forthcoming press releases will highlight groundbreaking clinical research, including Phase III trial results evaluating ...

Penn Medicine at the 2023 ASCO Annual Meeting

2023-05-25
CHICAGO –  Researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania will present data on the latest advances in clinical cancer research at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6 in Chicago, Illinois. Follow us on Twitter @PennMDForum and @PennCancer for updates. Expert Interviews Experts from the Perelman School of Medicine are available to comment on a wide range of topics in cancer science and medicine during the meeting on site and by video call, telephone, or email. To arrange interviews, please contact Meagan Raeke at Meagan.Raeke@pennmedicine.upenn.edu ...

Internal job candidates have a leg up

2023-05-25
AUSTIN, Texas – Internal job candidates have an advantage over external candidates, because they tend to work harder shortly before a hiring decision, according to new research from The University of Texas at Austin. This is true even when an internal candidate’s skills are inferior. Eric Chan, assistant professor of accounting at the McCombs School of Business, found that when a new job is on the line, employees will exert more effort to increase their chances of promotion — especially right before the decision. And managers are more likely ...

C. difficile, emerging pathogens, genomics, and antimicrobial resistance

C. difficile, emerging pathogens, genomics, and antimicrobial resistance
2023-05-25
A new study published in the peer-reviewed OMICS: A Journal of Integrative Biology identified genes for virulence and antimicrobial resistance in two bacteria that co-occur with C. difficile, suggesting these pathogens as emerging potential threats in planetary health. Click here to read the article now. Thokur Sreepathy Murali, PhD, Ankit Singh Tanwar, Padival Shruptha and colleagues from Manipal Academy of Higher Education, India, and co-author Angela Brand, MD, PhD, MPH from Maastricht University, The Netherlands, performed comparative genome analyses of three Clostridia species, ...

Groundbreaking images of root chemicals offer new insights on plant growth

Groundbreaking images of root chemicals offer new insights on plant growth
2023-05-25
On a sunny springtime stroll through a park, it’s easy to ignore the parts of plants that are hidden from view. Plant biologists see things differently. They look below the surface where plant roots are organized in elaborate systems that are critical to the organism’s development. Intricately organized tree root systems, for example, can span as far underground as the tree grows high above the soil. Applying an advanced imaging technology to plant roots, researchers at the University of California San Diego and Stanford University ...

LJI-led team wins top Nucleate honors for virus vaccine development proposal

2023-05-25
LA JOLLA, CA—A San Diego team, led by scientists at La Jolla Institute for Immunology (LJI), has won the top prizes in the Nucleate Activator competition. Out of 1,000 initial competitors, the LJI team advanced to the final four teams and swept all the prizes they entered for. Their winning research proposal outlines how scientists could stop dengue virus and Zika virus by developing sophisticated vaccines that activate both B cells and T cells. Nucleate is a student-led, non-profit organization dedicated to empowering early-stage, ...

Hydrogen battery: Storing hydrogen in coal may help power clean energy economy

Hydrogen battery: Storing hydrogen in coal may help power clean energy economy
2023-05-25
UNIVERSITY PARK, Pa. — The quest to develop hydrogen as a clean energy source that could curb our dependence on fossil fuels may lead to an unexpected place — coal. A team of Penn State scientists found that coal may represent a potential way to store hydrogen gas, much like batteries store energy for future use, addressing a major hurdle in developing a clean energy supply chain. “We found that coal can be this geological hydrogen battery,” said Shimin Liu, associate professor of energy and mineral engineering at Penn State. “You could inject and store the hydrogen energy and have it there when you need to use it.” Hydrogen ...

Artificial muscle fibers could serve as cell scaffolds

2023-05-25
In two new studies, North Carolina State University researchers designed and tested a series of textile fibers that can change shape and generate force like a muscle. In the first study, the researchers focused on the materials’ influence on artificial muscles’ strength and contraction length. The findings could help researchers tailor the fibers for different applications. In the second, proof-of-concept study, the researchers tested their fibers as scaffolds for live cells. Their findings suggest the fibers – known as “fiber robots” ...

Argonne hosts demo day for Lab-Embedded Entrepreneurship Program

2023-05-25
Twenty startups will present their technologies for a clean energy future at this year’s Lab-Embedded Entrepreneur Program (LEEP) Demo Day, June 7, in Chicago. LEEP connects entrepreneurs with resources and innovation ecosystems at U.S. Department of Energy (DOE) national labs.  In addition to demos from companies currently participating in LEEP, the event at the Sheraton Grand Chicago Riverwalk will also feature a panel discussion where program graduates share insights and advice about successful entrepreneurship. The technologies on display span renewable energy, materials for clean energy and water, batteries, ...

Helping virtual reality reflect social realities

Helping virtual reality reflect social realities
2023-05-25
Research on virtual reality is expanding as the technology grows, but too much of that research is being conducted with participants who don’t reflect the general population. The Virtual Experience Research Accelerator (VERA), a $5 million National Science Foundation-funded project, is creating a system to provide researchers with access to large, reliable, diverse groups of participants for an array of research projects on and using VR. “A lot of research in this area suffers from using participant samples ...

LAST 30 PRESS RELEASES:

Drug helps reprogram macrophage immune cells, suppress prostate and bladder tumor growth

Green infrastructure plans need to consider historical racial inequalities, say researchers

ENDO 2024 press conferences to highlight male birth control, anti-obesity medications

Highly sensitive fiber optic gyroscope senses rotational ground motion around active volcano

Research reveals endurance exercise training impacts biological molecules

Does managing oxidative stress hold the key to effectively treating Alzheimer’s disease

Warming climate intensifies flash droughts worldwide

US public health preparedness and response to highly pathogenic avian influenza A(H5N1) viruses

DRI to host AWE+ wildfire summit

MD Anderson Research Highlights for May 21, 2024

Polymer research aims to expand possibilities in sensor technology

New therapeutic avenues in bone repair

Socioeconomic status transition throughout life and risk of dementia

Climbing the social ladder slows dementia, Japanese study reveals

Researchers discover hidden step in dinosaur feather evolution

Studies reveal cell-by-cell changes caused when pig hearts and kidneys are transplanted into humans

SRI earns FDA Orphan Drug Designation for pancreatic cancer

A new gene-editing system tackles complex diseases

Tracking down toxic metals from tobacco smoke

Clarifying the cellular mechanisms underlying periodontitis with an improved animal model

Age, race impact AI performance on digital mammograms

SwRI leads courses at 2024 Society of Tribologists & Lubrication Engineers Annual Meeting

Hope for a cure for visceral leishmaniasis, an often fatal infectious disease

How AI helps programming a quantum computer

New research reveals that prehistoric seafloor pockmarks off the California coast are maintained by powerful sediment flows

AI can help improve ER admission decisions, Mount Sinai study finds

Matcha mouthwash inhibits bacteria that causes periodontitis

Oncology events in Poland solidify collaboration with NCCN

City of Hope awarded $5.4 million CIRM grant to create a stem cell laboratory and expand access to state-of-the-art disease models and technology among a diverse scientific community

Meeting preview: Hot topics at NUTRITION 2024

[Press-News.org] ASCO23: ‘Safety & efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid & CNS tumors’
Sylvester Comprehensive Cancer Center’s Dr. Macarena de la Fuente presents results from a Phase 1/2a study showing the experimental, targeted therapy may be effective in treating BRAF-altered solid tumors